BRIEF—BioNTech says 2021 revenues reached 19 billion euros

30 March 2022

Germany’s BioNTech, which has jumped into the limelight from near obscurity through the development of the most successful COVID-19 vaccine (Comirnaty) with US pharma giant Pfizer (NYSE: PFE), today reported financial results for the three months and full year ended December 31, 2021 and provided an update on its corporate progress.

The highlights of the announcement, which sent the firm’s shares up more than 4.6% to $180.34 pre-market, are as follows:

Fourth quarter and full year revenues of 5.5 billion euros ($6.05 billion) and 19.0 billion euros, respectively;
Full year net income of 10.3 billion euros and fully diluted earnings per share of 39.63 euros ($46.87);
BioNTech expects to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose a special cash dividend of 2.00 euros per share, pending approval at the Annual General Meeting;
Approximately 2.6 billion doses of Comirnaty/BNT162b2 were delivered to more than 165 countries and regions worldwide in 2021, including more than 1 billion doses to low- and middle-income countries;
BioNTech reiterates its COVID-19 2022 vaccine revenue guidance of 13 billion euros to 17 billion euros;
It has signed orders for 2022 delivery increased to 2.4 billion COVID-19 vaccine doses;
Expanded its clinical stage oncology pipeline to 16 clinical programs with initiation of nine clinical trials, including four randomized Phase II trials;
Initiated expansion of Phase III clinical trials to include Omicron-based vaccine candidates, and expanded mRNA vaccine pipeline with multiple preclinical programs addressing high-need infectious diseases expected to advance into the clinic this year; and
Focused on driving further transformation in 2022 by reinvesting COVID-19 vaccine profits to accelerate oncology and infectious disease programs, broaden pipeline and scale-up business.